Octagon Capital

Portfolio Co Investors 2026 for Octagon Capital: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Octagon Capital accounts for 11 tracked companies with verified cap-table data, 11 of which disclose round sizes totalling $1.7B. The median disclosed raise is $125M, and the largest is Harbour Biomed at $263M, ahead of Bluejay Therapeutics ($243M) and Hanyu Medical ($236M).

The names that recur most often on these co-invested cap tables are Octagon Capital (11 companies), OrbiMed (2 companies), RA Capital (2 companies), Decheng Capital (2 companies), Casdin Capital (2 companies), AEF Greater BAY Area Fund (1 company). By latest disclosed round, the market skews Series C (5), Series B (4), Series D (1), Series A (1).

Best funded Octagon Capital companies

  1. Harbour Biomed — $263M (latest: Series C)
  2. Bluejay Therapeutics — $243M (latest: Series C)
  3. Hanyu Medical — $236M (latest: Series D)
  4. EpimAb Biotherapeutics — $219M (latest: Series C)
  5. Century Therapeutics — $160M (latest: Series C)
  6. Hummingbird Bioscience — $125M (latest: Series C)
  7. Immune-Onc Therapeutics — $110M (latest: Series B)
  8. Allorion Therapeutics — $105M (latest: Series B)
  9. StrideBio — $82M (latest: Series B)
  10. Bioheng — $80M (latest: Series B)
  11. Vedere Bio — $77M (latest: Series A)

Octagon Capital Advisors LP — related firms and companies (56)

Octagon Capital Advisors LP profile · All research reports